Androgel is a drug owned by Besins Healthcare Ireland Ltd. It is protected by 15 US drug patents filed from 2013 to 2016. Out of these, 9 drug patents are active and 6 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 12, 2026. Details of Androgel's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9125816 | Pharmaceutical composition and method for treating hypogonadism |
Aug, 2020
(4 years ago) |
Expired
|
| US6503894 | Pharmaceutical composition and method for treating hypogonadism |
Aug, 2020
(4 years ago) |
Expired
|
| US9132089 | Pharmaceutical composition and method for treating hypogonadism |
Aug, 2020
(4 years ago) |
Expired
|
|
US6503894 (Pediatric) | Pharmaceutical composition and method for treating hypogonadism |
Mar, 2021
(3 years ago) |
Expired
|
|
US9132089 (Pediatric) | Pharmaceutical composition and method for treating hypogonadism |
Mar, 2021
(3 years ago) |
Expired
|
|
US9125816 (Pediatric) | Pharmaceutical composition and method for treating hypogonadism |
Mar, 2021
(3 years ago) |
Expired
|
| US8741881 | Testosterone gel and method of use |
Oct, 2026
(2 years from now) | Active |
| US8466136 | Testosterone gel and method of use |
Oct, 2026
(2 years from now) | Active |
| US8466137 | Testosterone gel and method of use |
Oct, 2026
(2 years from now) | Active |
| US8759329 | Testosterone gel and method of use |
Oct, 2026
(2 years from now) | Active |
| US8486925 | Testosterone gel and method of use |
Oct, 2026
(2 years from now) | Active |
| US8754070 | Testosterone gel and method of use |
Oct, 2026
(2 years from now) | Active |
| US8729057 | Testosterone gel and method of use |
Oct, 2026
(2 years from now) | Active |
| US8466138 | Testosterone gel and method of use |
Oct, 2026
(2 years from now) | Active |
| US8446138 | Stability compensation circuit and DC-DC converter including the same |
Oct, 2026
(2 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Androgel's patents.
Latest Legal Activities on Androgel's Patents
Given below is the list of recent legal activities going on the following patents of Androgel.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 23 Oct, 2023 | US9132089 (Litigated) |
| Expire Patent Critical | 16 Oct, 2023 | US9125816 (Litigated) |
| Maintenance Fee Reminder Mailed Critical | 08 May, 2023 | US9132089 (Litigated) |
| Maintenance Fee Reminder Mailed Critical | 01 May, 2023 | US9125816 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 11 Nov, 2021 | US8759329 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 11 Nov, 2021 | US8754070 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 11 Nov, 2021 | US8741881 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 14 Oct, 2021 | US8729057 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 18 Dec, 2020 | US8486925 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 28 Sep, 2020 | US8466137 |
Several oppositions have been filed on Androgel's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Androgel's generic, the next section provides detailed information on ongoing and past EP oppositions related to Androgel patents.
Androgel's Oppositions Filed in EPO
Androgel has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Aug 21, 2013, by Oser, Andreas. This opposition was filed on patent number EP06836341A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP06836341A | Aug, 2013 | Oser, Andreas | Opposition rejected |
US patents provide insights into the exclusivity only within the United States, but Androgel is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Androgel's family patents as well as insights into ongoing legal events on those patents.
Androgel's Family Patents
Try Our Curated Drug Screens
Generic Launch
Generic Release Date:
Androgel's generic launch date based on the expiry of its last outstanding patent is estimated to be Oct 12, 2026 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Androgel Generics:
Testosterone is the generic name for the brand Androgel. 15 different companies have already filed for the generic of Androgel, with Actavis Labs Ut Inc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Androgel's generic
Androgel Competitors
Understanding your competition is essential for market success. Androgel which is used for treating conditions associated with a deficiency or absence of endogenous testosterone in males., has several other brand drugs in the same treatment category and using the same active ingredient (Testosterone). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Eli Lilly And Co |
| |||
| Endo Operations |
| |||
| Tolmar |
| |||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Testosterone. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Acerus |
| ||
| Alza |
| ||
| Antares Pharma Inc |
| ||
| Auxilium Pharms Llc |
| ||
| Endo Operations |
| ||
| Marius Pharms Llc |
| ||
| Slayback Pharma Llc |
| ||
| Upsher Smith Labs |
| ||
| Verity |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Testosterone, Androgel's active ingredient. Check the complete list of approved generic manufacturers for Androgel
About Androgel
Androgel is a drug owned by Besins Healthcare Ireland Ltd. It is used for treating conditions associated with a deficiency or absence of endogenous testosterone in males. Androgel uses Testosterone as an active ingredient. Androgel was launched by Besins Hlthcare in 2003.
Approval Date:
Androgel was approved by FDA for market use on 26 September, 2003.
Active Ingredient:
Androgel uses Testosterone as the active ingredient. Check out other Drugs and Companies using Testosterone ingredient
Treatment:
Androgel is used for treating conditions associated with a deficiency or absence of endogenous testosterone in males.
Dosage:
Androgel is available in the following dosage forms - gel, metered form for transdermal use, gel form for transdermal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 12.5MG/1.25GM ACTUATION **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | GEL, METERED | Discontinued | TRANSDERMAL |
| 25MG/2.5GM PACKET **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | GEL | Discontinued | TRANSDERMAL |
| 50MG/5GM PACKET **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | GEL | Discontinued | TRANSDERMAL |
| 1.62% (20.25MG/1.25GM ACTUATION) | GEL, METERED | Prescription | TRANSDERMAL |
| 1.62% (20.25MG/1.25GM PACKET) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | GEL | Discontinued | TRANSDERMAL |
| 1.62% (40.5MG/2.5GM PACKET) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | GEL | Discontinued | TRANSDERMAL |